OBJECTIVE: To describe the contemporary features of coagulase-negative staphylococcal (CoNS) prosthetic valve endocarditis (PVE). DESIGN: Observational study of prospectively collected data from a multinational cohort of patients with infective endocarditis. Patients with CoNS PVE were compared to patients with Staphylococcus aureus and viridans streptococcal (VGS) PVE. SETTING: The International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) is a contemporary cohort of patients with infective endocarditis from 61 centres in 28 countries. PATIENTS: Adult patients in the ICE-PCS with definite PVE and no history of injecting drug use from June 2000 to August 2005 were included. INTERVENTIONS: None. MAIN OUTCOME MEASURES: Heart failure, intracardiac abscess, death. RESULTS: CoNS caused 16% (n = 86) of 537 cases of definite non-injecting drug use-associated PVE. Nearly one-half (n = 33/69, 48%) of patients with CoNS PVE presented between 60 days and 365 days of valve implantation. The rate of intracardiac abscess was significantly higher in patients with CoNS PVE (38%) than in patients with either S aureus (23%, p = 0.03) or VGS (20%, p = 0.05) PVE. The rate of abscess was particularly high in early (50%) and intermediate (52%) CoNS PVE. In-hospital mortality was 24% for CoNS PVE, 36% for S aureus PVE (p = 0.09) and 9.1% for VGS PVE (p = 0.08). Meticillin resistance was present in 68% of CoNS strains. CONCLUSIONS: Nearly one-half of CoNS PVE cases occur between 60 days and 365 days of prosthetic valve implantation. CoNS PVE is associated with a high rate of meticillin resistance and significant valvular complications.
OBJECTIVE: To describe the contemporary features of coagulase-negative staphylococcal (CoNS) prosthetic valve endocarditis (PVE). DESIGN: Observational study of prospectively collected data from a multinational cohort of patients with infective endocarditis. Patients with CoNS PVE were compared to patients with Staphylococcus aureus and viridans streptococcal (VGS) PVE. SETTING: The International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) is a contemporary cohort of patients with infective endocarditis from 61 centres in 28 countries. PATIENTS: Adult patients in the ICE-PCS with definite PVE and no history of injecting drug use from June 2000 to August 2005 were included. INTERVENTIONS: None. MAIN OUTCOME MEASURES: Heart failure, intracardiac abscess, death. RESULTS: CoNS caused 16% (n = 86) of 537 cases of definite non-injecting drug use-associated PVE. Nearly one-half (n = 33/69, 48%) of patients with CoNS PVE presented between 60 days and 365 days of valve implantation. The rate of intracardiac abscess was significantly higher in patients with CoNS PVE (38%) than in patients with either S aureus (23%, p = 0.03) or VGS (20%, p = 0.05) PVE. The rate of abscess was particularly high in early (50%) and intermediate (52%) CoNS PVE. In-hospital mortality was 24% for CoNS PVE, 36% for S aureus PVE (p = 0.09) and 9.1% for VGS PVE (p = 0.08). Meticillin resistance was present in 68% of CoNS strains. CONCLUSIONS: Nearly one-half of CoNS PVE cases occur between 60 days and 365 days of prosthetic valve implantation. CoNS PVE is associated with a high rate of meticillin resistance and significant valvular complications.
Authors: B Zaloudíková; E Němcová; J Pol; Z Sorm; S Wurmová; K Novotná; M Vaněrková; V Holá; F Růžička; L Dušek; P Němec; T Freiberger Journal: Eur J Clin Microbiol Infect Dis Date: 2011-10-02 Impact factor: 3.267
Authors: Anh K Lam; Melissa A Hill; Erika L Moen; Jennifer Pusavat; Cassandra L Wouters; Charles V Rice Journal: ChemMedChem Date: 2018-09-25 Impact factor: 3.466
Authors: C García-de-la-Mària; F Marco; Y Armero; D Soy; A Moreno; A del Río; M Almela; C Cervera; S Ninot; C Falces; C A Mestres; J M Gatell; M T Jiménez de Anta; J M Miró Journal: Antimicrob Agents Chemother Date: 2010-04-26 Impact factor: 5.191
Authors: Sadia A Niazi; Douglas Clarke; Thuy Do; Steven C Gilbert; Francesco Mannocci; David Beighton Journal: J Clin Microbiol Date: 2010-08-25 Impact factor: 5.948
Authors: M Carugati; C A Petti; C Arnold; J M Miro; J M Pericàs; C Garcia de la Maria; Z Kanafani; E Durante-Mangoni; J Baddley; D Wray; J L Klein; F Delahaye; N Fernandez-Hidalgo; M M Hannan; D Murdoch; A Bayer; V H Chu Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191